Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.79 |
| ▸ | EGFR | P00533 | 16/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878756 | 0.94 | EGFR (0.70) | BRAFEGFR | |
| SCHEMBL13878776 | 0.92 | BRAF (0.67) | BRAFEGFR | |
| SCHEMBL13878775 | 0.92 | BRAF (0.67) | BRAFEGFRCSF1RKIT | |
| SCHEMBL13878785 | 0.92 | EGFR (0.67) | BRAFEGFR | |
| SCHEMBL13878771 | 0.91 | BRAF (0.78) | BRAFEGFRCSF1RKIT | |
| SCHEMBL13878819 | 0.90 | BRAF (0.64) | BRAFEGFRCSF1RKIT | |
| SCHEMBL13878763 | 0.86 | BRAF (0.74) | BRAFEGFRABL1CSF1RKIT | |
| SCHEMBL13878755 | 0.85 | HTT (0.69) | BRAFEGFR | |
| SCHEMBL13891397 | 0.83 | EGFR (0.55) | BRAFEGFR | |
| SCHEMBL13878774 | 0.83 | BRAF (0.65) | BRAFEGFRCSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | BRAF 8/4885EGFR 42/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.